Most medical writing teams do not have a writing problem. They have a reuse problem. The same efficacy result appears in the protocol, the clinical study report, the investigator brochure, the summary documents and a dozen responses to regulators, and every copy is maintained by hand.
An enterprise authoring platform is meant to fix that. Many do not, because they solve document storage instead. This is how to tell the difference.
Storage is not authoring
A document management system stores files, controls versions and routes approvals. That is useful, and most regulated organisations already have one.
An authoring platform is meant to do something harder: keep the content inside those documents consistent with its source, and with every other document that uses it. If a platform cannot tell you which documents contain a given result, and update or flag them when the result changes, it is a repository with a nicer editor.
The test that separates them
Take one real number, such as a primary endpoint result, and ask the vendor three questions.
- Where does this number appear across all our documents?
- If the analysis is re-run and the number changes, what happens to each of those places?
- Can a reviewer see, in each document, where the number came from?
A storage system answers the first question with a search. An authoring platform answers all three, because it treats the number as a single fact with many uses rather than many separate pieces of text.
What it should never do
Draft clinical interpretation. Conclusions, benefit-risk reasoning and causality are judgements made by qualified people, and they are the reason those people sign the document.
A platform that drafts the descriptive content, keeps it consistent with source and leaves the reasoning alone is doing the right job. One that offers to write the discussion section is solving the wrong problem and creating a new risk.
Validation and Part 11
Content produced on the platform becomes part of regulated submissions, so the platform is a computerised system and validates as one. That means the usual controls, applied for real: attributable changes, a tamper-evident audit trail, proper electronic signatures, and retention that keeps the original reachable.
If the platform uses AI, add the AI-specific questions: a stated intended use, evaluation before release, monitoring for drift, and a working fallback. The draft EU GMP Annex 22 is not in force, but it shows where expectations are heading. Our AI validation page goes further.
Adoption is the real risk
Most authoring platform projects do not fail on technology. They fail because writers keep working in Word and paste into the platform at the end, which gives you all the cost and none of the benefit.
The fix is to start with one document type where reuse is obvious, such as the investigator brochure, and prove the time saving there before widening the scope. A platform that only works if everyone changes how they write on day one will not get used.
Where we fit
TraceDraft is built around source traceability: every statement linked to its origin, consistency checked across documents, and the judgement left with your writers. Our medical writing team works the same way. If you want to test it on one of your own document sets, get in touch.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.